Medicine

Molecular profiling of BRAF-V600E-mutant metastatic intestines cancer in the phase\u00e2 $ 3 LIGHTHOUSE CRC test

.Competing enthusiasms.S.K.: Supply and also Other Possession Enthusiasms: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Duty: AbbVie, Amal Therapeutics, AstraZeneca/MedImmune, Bayer Health, Bicara Therapies, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Effort BioMedicines, Flame Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Health Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapeutics, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Analysis Financing: Amgen (Inst), Array BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Formerly Pfizer. Supply and Various Other Ownership Passions: Pfizer. J.P.: Job: Formerly Pfizer. Inventory as well as Various Other Ownership Claims: Pfizer. F.C.: Consulting or even Advisory Role: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Study Financing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or Advisory Role: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Research Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Duty: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or even Advisory Task: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Med), Zymeworks. Research Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Research Study Funding: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Job: Pfizer. Supply as well as Various Other Ownership Interests: Pfizer. X.Z.: Job: Pfizer. Stock and also Various Other Possession Claims: Pfizer. Patents, Aristocracies, Other Patent: Johns Hopkins Educational Institution. P.H.: Job: Pfizer. Supply as well as Various Other Possession Interests: Pfizer. T.X.: Work: Pfizer. Inventory and also Various Other Ownership Claims: Pfizer. R.Y.: Consulting or even Advisory Function: Variety BioPharma/Pfizer, Mirati Rehabs, Zai Lab, Amgen. Analysis Funding: Variety BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapeutics (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Role: Collection BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapies, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Therapy, TheraMyc. Other Partnership: Amgen, Collection Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Research UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Converse el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Wellness KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Principle for Medical Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education And Learning Information, Sanofi-Aventis, Servier, Taiho Drug.